Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Gains from Sales and Divestitures (2018 - 2025)

Historic Gains from Sales and Divestitures for Revolution Medicines (RVMD) over the last 8 years, with Q3 2025 value amounting to $978467.0.

  • Revolution Medicines' Gains from Sales and Divestitures rose 3496.75% to $978467.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $978467.0, marking a year-over-year increase of 3496.75%. This contributed to the annual value of $1.0 million for FY2024, which is 7526.87% up from last year.
  • Latest data reveals that Revolution Medicines reported Gains from Sales and Divestitures of $978467.0 as of Q3 2025, which was up 3496.75% from $633511.0 recorded in Q2 2025.
  • Revolution Medicines' 5-year Gains from Sales and Divestitures high stood at $1.0 million for Q4 2024, and its period low was $1798.0 during Q1 2021.
  • Over the past 5 years, Revolution Medicines' median Gains from Sales and Divestitures value was $260143.0 (recorded in 2023), while the average stood at $335960.6.
  • As far as peak fluctuations go, Revolution Medicines' Gains from Sales and Divestitures soared by 454069.01% in 2021, and later surged by 3496.75% in 2025.
  • Quarter analysis of 5 years shows Revolution Medicines' Gains from Sales and Divestitures stood at $78010.0 in 2021, then surged by 257.45% to $278848.0 in 2022, then surged by 106.91% to $576974.0 in 2023, then soared by 75.27% to $1.0 million in 2024, then dropped by 3.24% to $978467.0 in 2025.
  • Its Gains from Sales and Divestitures was $978467.0 in Q3 2025, compared to $633511.0 in Q2 2025 and $271536.0 in Q1 2025.